Form D To Observe: Ternus Pharma $1.00 million Fundraising. Marc R Cote Submitted Nov 7 Form D

Pharmaceuticals Ternus Pharma, Inc. - Marc R Cote

Ternus Pharma Financing

Ternus Pharma, Inc., Corporation just had published form D because of $1.00 million debt financing. This is a new filing. Ternus Pharma was able to finance itself with $185,000 so far. That is 18.50% of the financing round. The total offering amount was $1.00 million. The financing document was filed on 2016-11-07. The reason for the financing was: unspecified. The fundraising still has about $815,000 more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Ternus Pharma is based in Massachusetts. The firm’s business is Pharmaceuticals. The SEC form was submitted by Marc R Cote Treasurer. The company was incorporated in 2014. The filler’s address is: 130 Tobey Garden Street, Duxbury, Ma, Massachusetts, 02332. Marc R. Cote is the related person in the form and it has address: C/O Ternus Pharma, Inc., 130 Tobey Garden Street, Duxbury, Ma, Massachusetts, 02332. Link to Ternus Pharma Filing: 000168860816000001.

Analysis of Ternus Pharma Offering

On average, companies in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Ternus Pharma sold 18.50% of the offering. The financing is still open. The average investment offering size for companies in the Pharmaceuticals industry is $556,000. The offering was 66.73% smaller than the average of $556,000. Of course this should not be interpreted as negative. Startups raise funds for a variety of reasons and needs. The minimum investment for this financing was set at $25000. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Ternus Pharma Also

The Form D signed by Marc R Cote might help Ternus Pharma, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment